Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) predominantly affects individuals aged > 60 years who have several comorbidities. Nintedanib is an approved treatment for IPF, which reduces the rate of decline in forced vital capacity (FVC). We assessed the efficacy and safety of nintedanib in pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Glaspole, Ian, Bonella, Francesco, Bargagli, Elena, Glassberg, Marilyn K., Caro, Fabian, Stansen, Wibke, Quaresma, Manuel, Orsatti, Leticia, Bendstrup, Elisabeth
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073950/
https://ncbi.nlm.nih.gov/pubmed/33902584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01695-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados